Characterization of LY2775240, a selective phosphodiesterase‐4 inhibitor, in nonclinical models and in healthy subjects

by Dipak R. Patel, Shweta Urva, Stephen Ho, Cody J. Buckman, Yanfei Ma, Jean Lim, Sean E. Sissons, Mary S. Zuniga, Diane Philips, Karen Cox, Daniel J. Dairaghi
Published 2021-05-01

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

by Tamer Coskun, Kyle W. Sloop, Corina Loghin, Jorge Alsina-Fernandez, Shweta Urva, Krister B. Bokvist, Xuewei Cui, Daniel A. Briere, Over Cabrera, William C. Roell, Uma Kuchibhotla, Julie S. Moyers, Charles T. Benson, Ruth E. Gimeno, David A. D'Alessio, Axel Haupt
Published 2018-12-01

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

by Francis S. Willard, Jonathan D. Douros, Maria B.N. Gabe, Aaron D. Showalter, David B. Wainscott, Todd M. Suter, Megan E. Capozzi, Wijnand J.C. van der Velden, Cynthia Stutsman, Guemalli R. Cardona, Shweta Urva, Paul J. Emmerson, Jens J. Holst, David A. D’Alessio, Matthew P. Coghlan, Mette M. Rosenkilde, Jonathan E. Campbell, Kyle W. Sloop
Published 2020-09-01